‘I wanted to help another family’

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-27T13:21:09.302Z • Permanent link

Mireille Krougher, a renowned surrogacy agency founder, has been at the center of a stormy controversy surrounding the industry. The American College of Obstetricians and Gynecologists (ACOG) has released a statement emphasizing the importance of informed consent in surrogacy, citing Krougher's agency as a prime example. Krougher's agency, in turn, has accused ACOG of imposing undue regulations on the industry, which she claims will lead to a shortage of available surrogates.

Over the past few months, Krougher's agency has been embroiled in a heated debate with the National Infertility Association (NIA) over the best practices for surrogacy. Krougher's agency has developed its own set of guidelines, which prioritize the interests of both intended parents and surrogate mothers. The NIA, on the other hand, has advocated for stricter regulations, citing concerns about the exploitation of surrogate mothers.

Meanwhile, the U.S. Department of Health and Human Services has announced plans to introduce new regulations governing the commercial surrogacy industry. These regulations are expected to address concerns about the welfare of surrogate mothers and the ethics of surrogacy. Krougher's agency has expressed its support for these regulations, arguing that they will help to establish a more transparent and accountable industry.

Regulatory changes in the surrogacy industry are likely to have far-reaching consequences for companies involved in commercial surrogacy. Companies such as Reproductive Medicine Associates (RMA) and Fertility Centers of New England (FCNE) are already preparing for the potential impact of new regulations. Research communities, such as the American Society for Reproductive Medicine (ASRM), are also likely to be affected, as new regulations will likely shape the way that research is conducted in the field.

The potential shortage of available surrogates could have significant implications for the fertility treatment market, which is expected to grow in the coming years. Companies such as 23andMe and AncestryDNA, which offer genetic testing services, may also be affected, as surrogacy is increasingly becoming a more accessible option for individuals and couples seeking to build their families.

The controversy surrounding surrogacy is part of a larger debate about reproductive rights and the ethics of assisted reproduction. Similar debates have been taking place in countries such as the United Kingdom, where the Human Fertilisation and Embryology Authority (HFEA) has introduced new regulations governing the use of assisted reproductive technologies. In some countries, such as India, surrogacy is a highly commercialized industry, with many agencies offering services to intended parents from around the world.